Literature DB >> 25527046

High expression of CXCR3 is an independent prognostic factor in glioblastoma patients that promotes an invasive phenotype.

Yi Pu1, Shouwei Li, Chuanbao Zhang, Zhaoshi Bao, Zhengxiang Yang, Lihua Sun.   

Abstract

Chemokines are a superfamily of small heparin-binding cytokines that induce leukocytes to migrate to sites of inflammation or injury through interacting with specific transmembrane G protein-coupled receptors. Currently, attention is focused on chemokine/chemokine receptor pairs and their ability to promote tumor cell migration and angiogenesis. The chemokine receptor CXCR3 is involved in tumor metastasis and is used as a prognostic biomarker. However, its relationship with the clinicopathological features of primary glioblastoma multiforme (pGBM) and its potential prognostic value have yet to be investigated. Here, we report that high CXCR3 expression conferred poor survival in pGBM patients. Further analysis showed that CXCR3 served as an independent prognostic biomarker for pGBM patients. In addition, functional assays indicated that CXCR3 induced glioma cell invasion. Therefore, this evidence indicates CXCR3 is an independent prognostic factor for pGBM patients and promotes an invasive phenotype, which suggests a new potential biotarget for glioblastoma multiforme therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25527046     DOI: 10.1007/s11060-014-1692-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  32 in total

1.  The prognostic significance of chemokine receptor CXCR3 expression in colorectal carcinoma.

Authors:  Zhenqian Wu; Xiaodong Han; Jun Yan; Ye Pan; Jianfeng Gong; Jianzhong Di; Zhe Cheng; Zhiming Jin; Zhigang Wang; Qi Zheng; Yu Wang
Journal:  Biomed Pharmacother       Date:  2012-02-17       Impact factor: 6.529

2.  Chemokine receptor CXCR3 promotes growth of glioma.

Authors:  Che Liu; Defang Luo; Brent A Reynolds; Geeta Meher; Alan R Katritzky; Bao Lu; Craig J Gerard; Cyrus P Bhadha; Jeffrey K Harrison
Journal:  Carcinogenesis       Date:  2010-11-03       Impact factor: 4.944

3.  Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer.

Authors:  Tonya C Walser; Salah Rifat; Xinrong Ma; Namita Kundu; Chris Ward; Olga Goloubeva; Michael G Johnson; Julio C Medina; Tassie L Collins; Amy M Fulton
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

4.  MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10.

Authors:  Lihua Sun; Wei Yan; Yingyi Wang; Guan Sun; Hui Luo; Junxia Zhang; Xiefeng Wang; Yongping You; Zhengxiang Yang; Ning Liu
Journal:  Brain Res       Date:  2011-03-16       Impact factor: 3.252

5.  Potential role of miRNAs and their inhibitors in glioma treatment.

Authors:  Kaveh Asadi-Moghaddam; E Antonio Chiocca; Sean E Lawler
Journal:  Expert Rev Anticancer Ther       Date:  2010-11       Impact factor: 4.512

Review 6.  Molecular mechanisms of glioma cell migration and invasion.

Authors:  Tim Demuth; Michael E Berens
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

7.  Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes.

Authors:  K Kawada; H Hosogi; M Sonoshita; H Sakashita; T Manabe; Y Shimahara; Y Sakai; A Takabayashi; M Oshima; M M Taketo
Journal:  Oncogene       Date:  2007-02-05       Impact factor: 9.867

Review 8.  The chemokine receptors CXCR4 and CXCR3 in cancer.

Authors:  Amy M Fulton
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

9.  CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.

Authors:  C Monteagudo; J M Martin; E Jorda; A Llombart-Bosch
Journal:  J Clin Pathol       Date:  2006-03-07       Impact factor: 3.411

10.  Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism.

Authors:  B Cambien; B F Karimdjee; P Richard-Fiardo; H Bziouech; R Barthel; M A Millet; V Martini; D Birnbaum; J Y Scoazec; J Abello; T Al Saati; M G Johnson; T J Sullivan; J C Medina; T L Collins; A Schmid-Alliana; H Schmid-Antomarchi
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

View more
  19 in total

1.  Overexpression of Paxillin Correlates with Tumor Progression and Predicts Poor Survival in Glioblastoma.

Authors:  Li-Hua Sun; Fu-Qiang Yang; Chuan-Bao Zhang; Yi-Ping Wu; Jing-Shan Liang; Shuai Jin; Zheng Wang; Hong-Jun Wang; Zhao-Shi Bao; Zheng-Xiang Yang; Tao Jiang
Journal:  CNS Neurosci Ther       Date:  2016-09-17       Impact factor: 5.243

Review 2.  The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment.

Authors:  Andreas Bikfalvi; Clotilde Billottet
Journal:  Am J Physiol Cell Physiol       Date:  2020-01-08       Impact factor: 4.249

Review 3.  Evolution, Expression and Functional Analysis of CXCR3 in Neuronal and Cardiovascular Diseases: A Narrative Review.

Authors:  Devi Satarkar; Chinmoy Patra
Journal:  Front Cell Dev Biol       Date:  2022-06-20

Review 4.  Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy.

Authors:  Gregory P Takacs; Joseph A Flores-Toro; Jeffrey K Harrison
Journal:  Pharmacol Ther       Date:  2020-12-11       Impact factor: 12.310

5.  Hormones and immunity in cancer: are thyroid hormones endocrine players in the microglia/glioma cross-talk?

Authors:  Cristiana Perrotta; Clara De Palma; Emilio Clementi; Davide Cervia
Journal:  Front Cell Neurosci       Date:  2015-06-23       Impact factor: 5.505

6.  Positive expression of KIF20A indicates poor prognosis of glioma patients.

Authors:  Jia Duan; Wei Huang; Haiping Shi
Journal:  Onco Targets Ther       Date:  2016-11-02       Impact factor: 4.147

7.  KIF23 is an independent prognostic biomarker in glioma, transcriptionally regulated by TCF-4.

Authors:  Lihua Sun; Chuanbao Zhang; Zhengxiang Yang; Yiping Wu; Hongjun Wang; Zhaoshi Bao; Tao Jiang
Journal:  Oncotarget       Date:  2016-04-26

8.  CXCR3 mediates ascites-directed tumor cell migration and predicts poor outcome in ovarian cancer patients.

Authors:  C Windmüller; D Zech; S Avril; M Boxberg; T Dawidek; B Schmalfeldt; M Schmitt; M Kiechle; H Bronger
Journal:  Oncogenesis       Date:  2017-05-15       Impact factor: 7.485

9.  Ligand activation induces different conformational changes in CXCR3 receptor isoforms as evidenced by plasmon waveguide resonance (PWR).

Authors:  K Boyé; C Billottet; N Pujol; I D Alves; A Bikfalvi
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

10.  Serpin peptidase inhibitor, clade A member 3 (SERPINA3), is overexpressed in glioma and associated with poor prognosis in glioma patients.

Authors:  Dingyuan Luo; Wei Chen; Yun Tian; Junliang Li; Xinke Xu; Cheng Chen; Fangcheng Li
Journal:  Onco Targets Ther       Date:  2017-04-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.